Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.

In Oncology
by ClinOwl

IrAEs typically occur within 4 months of starting anti-PD1-based therapy (anti-PD1 +/- anti-CTLA4), but delayed irAEs (onset >12 months after commencement) can also occur. This study describes the incidence, nature […]